HIV prevention research and COVID-19: putting ethics guidance to the test

Author:

Rennie Stuart,Chege Wairimu,Schrumpf Leah A.,Luna Florencia,Klitzman Robert,Moseki Ernest,Brown Brandon,Wakefield Steven,Sugarman JeremyORCID

Abstract

Abstract Background Critical public health measures implemented to mitigate the spread of the novel coronavirus disease (COVID-19) pandemic have disrupted health research worldwide, including HIV prevention research. While general guidance has been issued for the responsible conduct of research in these challenging circumstances, the contours of the dueling COVID-19 and HIV/AIDS pandemics raise some critical ethical issues for HIV prevention research. In this paper, we use the recently updated HIV Prevention Trials Network (HPTN) Ethics Guidance Document (EGD) to situate and analyze key ethical challenges related to the conduct of HIV prevention research during the COVID-19 pandemic as well as identify potential areas for refinement of the guidance document based on this unprecedented state of affairs. Main body Necessary actions taken for HIV prevention research studies due to the COVID-19 pandemic involve an array of ethical issues including those related to: (1) risk mitigation; (2) behavior change; (3) compounding vulnerability; (4) community engagement; (5) trial reopening; and 6) shifting research priorities. Conclusions In the context of the dueling HIV and COVID-19 global pandemics, research teams and sponsors must be nimble in responding to the rapidly changing environment by being sensitive to the associated ethical issues. The HTPN EGD provides a rich set of tools to help identify, analyze and address many of these issues. At the same time, future refinements of the HPTN EGD and other research ethics guidance could be strengthened by providing explicit advice regarding the ethical issues associated with disrupted research and the reopening of studies. In addition, additional consideration should be given to appropriately balancing domains of risk (e.g., physical versus social), addressing the vulnerability of research staff and community partners, and responding to un-anticipatable ancillary care needs of participants and communities. Appropriately addressing these issues will necessitate conceptual work, which would benefit from the careful documentation of the actual ethical issues encountered in research, the strategies implemented to overcome them, and their success in doing so. Throughout all of these efforts, it is critical to remember that the HIV pandemic not be forgotten in the rush to deal with the COVID-19 pandemic.

Funder

National Institute of Allergy and Infectious Diseases

Publisher

Springer Science and Business Media LLC

Subject

Health Policy,Health (social science),Issues, ethics and legal aspects

Reference38 articles.

1. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): How to Protect Yourself & Others. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html. Accessed 03 Nov 2020.

2. Pinto RM, Park S. COVID-19 Pandemic Disrupts HIV Continuum of Care and Prevention: implications for Research and Practice Concerning Community-Based Organizations and Frontline Providers. AIDS Behav. 2020. https://doi.org/10.1007/s10461-020-02893-3.

3. Chenneville T, Gabbidon K, Hanson P, Holyfield C. The impact of COVID-19 on HIV treatment and research: a call to action. Int J Environ Res Public Health. 2020. https://doi.org/10.3390/ijerph17124548.

4. U.S. Food and Drug Administration. FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-COVID-19-public-health-emergency. Accessed 8 Jun 2020.

5. National Institutes of Health. Notice Files: Guidance for NIH-funded Clinical Trials and Human Subjects Studies Affected by COVID-19. 2020 https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-087.html. Accessed 8 Jun 2020.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3